Snowdome 2024 Haematology fellowship for work in AL amyloidosis
The AAN warmly congratulates Muhammed B. Sabdia, a final year PhD student at the Mater Research Institute, The [...]
PBAC invites submissions from ATTRv patients with neuropathy (now expired)
If you a patient with ATTRv with polyneuropathy, or a carer, friend, family member or health professional treating a [...]
Report from ISA Congress 2024 (Rochester)
The International Society of amyloidosis Congress was a fantastic week-long conference on all aspects of amyloidosis held in Rochester, Minnesota, [...]
Leukaemia Foundation launches new Optimal Care Pathways
The Leukaemia Foundation launches new Optimal Care Pathways or OCPs designed to improve patient outcomes by ensuring specialists, hospitals, [...]
Australian National Amyloidosis Day May 8, 2024 – video now available
May 8, Australian National Amyloidosis Day is a very important day for raising awareness about the group of complicated [...]
Tafamidis for ATTR CA listed on the PBS from May 1
PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure.For more detailed [...]
AAN Mayo Clinic Travel Grant Winners
Congratulations to the three young researchers who are heading to the International Symposium of Amyloidosis at the Mayo Clinic on [...]
Mrs Patricia Neely – Member of the Order of Australia (AM)
Congratulations to our Pat Neely, newly appointed Member of the Order of Australia for her services for the [...]
PBAC recommends patisiran for ATTRv with neuropathy
Patisiran has been recommended by the Pharmaceutical Benefits Advisory Committee for those with hereditary transthyretin amyloidosis with polyneuropathy. [...]
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Abstract Background Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in the heart. [...]
Consensus recommendations on holistic care in hereditary ATTR amyloidosis
Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life- limiting multisystem disease, affecting every aspect of a patient’s [...]
Positive progress towards Medicare funded access to Tafamidis and Patisiran for ATTR
PBAC has recommended PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II [...]
